Eli Lilly And Co. (LLY) News Headlines

▮ More

Date

Headline

9/16/2021 5:26:24 PM FDA Expands EUA For Lilly's Bamlanivimab, Etesevimab To Include Post-exposure Prophylaxis For COVID

9/15/2021 7:04:48 AM Lilly To Supply 388,000 Doses Of Etesevimab To U.S. For Treatment Of COVID-19

9/14/2021 12:15:08 PM Eli Lilly And Co To Participate In The Morgan Stanley Global Healthcare Conference At 1:15 PM ET

9/13/2021 8:06:53 AM Lilly To Present New Data From Oncology Portfolio At ESMO Congress; To Be Held Virtually September 16-21

9/9/2021 8:46:51 AM Eli Lilly Reports Breakthrough Therapy Designation For Jardiance - Quick Facts

9/9/2021 8:45:12 AM Eli Lilly And Co. To Present At Citi's BioPharma Virtual Conference; Webcast At 9:45 AM ET

9/7/2021 6:16:34 AM Eli Lilly Begins Cash Tender Offer Of Specified Series Of Outstanding Debt Securities

9/7/2021 6:02:26 AM Lilly Begins Cash Tender Offer For Up To $1.5 Bln Combined Aggregate Principal Amount Of Debt Securities

8/25/2021 7:07:21 AM Eli Lilly To Utilize Lycia's LYTAC Platform To Treat Challenging Disease Areas

8/25/2021 6:58:14 AM Lilly Says Carolyn Bertozzi Resigns From Board - Quick Facts

8/25/2021 6:50:29 AM Lilly, Lycia Therapeutics Enter Strategic Collaboration To Develop Novel Lysosomal Targeting Chimera Degraders

8/25/2021 6:47:56 AM Lilly Announces Carolyn Bertozzi Resigns From Board

8/23/2021 8:15:21 AM Medigen Vaccine Biologics Announces Rollout Of COVID-19 Vaccine In Taiwan

8/20/2021 6:12:31 AM Spotify To Buy Back Up To $1.0 Bln Of Stock

8/17/2021 7:09:38 AM Eli Lilly Creates Separate Divisions For Neuroscience And Immunology - Quick Facts

8/17/2021 6:36:45 AM Lilly Announces Executive Leadership Changes And Creation Of Neuroscience And Immunology Business Units

8/16/2021 7:21:46 AM FDA Approves Pump Use For Lilly's Insulin

8/16/2021 7:01:46 AM Lilly Says FDA Approves Lyumjev 100 Units/mL For Use In Insulin Pumps

8/16/2021 2:31:10 AM Lilly: Lebrikizumab Meets Primary, Secondary Goals In ADvocate 1, ADvocate 2 Phase 3 Trials

8/16/2021 2:02:09 AM Lilly's Lebrikizumab Meet Endpoints In ADvocate 1 And ADvocate 2 Phase 3 Clinical Trials